Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Otoscopic exams critical for accurate diagnosis of ear infections in children

Among the findings of an analysis of previous studies regarding ear infections in children are that results from otoscopic exams (an instrument for examining the interior of the ear) are critical to accurate diagnosis and antibiotics are modestly more effective than no treatment, with most antibiotics demonstrating similar rates of clinical success among children at normal risk, according to an article in the November 17 issue of JAMA.

17 Nov 2010

New inhalable dry powder antibiotic may reduce TB treatment time

New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.

17 Nov 2010

FDA partners with CDC to kick off Get Smart about Antibiotics Week

This year, millions of antibiotics will be prescribed. Antibiotics can be used to treat bacterial infections; however, they are commonly over-prescribed. Patients sometimes ask their health care professional to prescribe antibiotic drugs for viral infections, like the common cold, despite the fact that they will not work and may lead to potentially harmful side effects. The misuse of antibiotics has contributed to one of the world's most pressing public health problems today, antibiotic resistance.

17 Nov 2010

UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, Amherst (UMass), have received a Phase 2 Small Business Technology Transfer (STTR) contract in the amount of $750,000.

17 Nov 2010

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.

17 Nov 2010

National campaign to highlight significance of antibiotic resistance

Antibiotic resistance is one of the world's most pressing public health threats. To bring attention to this increasing problem, the Centers for Disease Control and Prevention and other government partners will observe its third annual Get Smart About Antibiotics Week on Nov. 15-21, 2010.

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Deinobiotics project receives €1.35 million for developing novel antibiotic, antifungal compounds

Deinove, the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced that its Deinobiotics project is to receive a total of €1.35 million in grants and loans.

15 Nov 2010

Report documents increase in R&D projects on developing world diseases

Drugmakers are now working on over 100 R&D projects designed to tackle diseases of the developing world and almost 80% of them are being carried out with non-industry partners, according to a report released on Wednesday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

15 Nov 2010

Research on E.Coli bacteria could help develop new vaccine for urinary tract infection

Urinary tract infections are a painful, recurring problem for millions of women. They are also getting more dangerous as bacteria develop resistance to the most common treatments.

15 Nov 2010

Targeted Genetics enters definitive agreements to acquire Biocontrol

Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.

12 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

Aradigm Corporation today announced financial results for the third quarter and nine months ended September 30, 2010.

11 Nov 2010

MqsA and MqsR protein complex can disrupt drug-resistant biofilm formation

When a foreign object such as a catheter enters the body, bacteria may not only invade it but also organize into a slick coating - a biofilm - that is highly resistant to antibiotics. Like sophisticated organized crime rings, biofilms cannot be defeated by a basic approach of conventional means. Instead doctors and drug developers need sophisticated new intelligence that reveals the key players in the network and how they operate. New research led by biologists at Brown University provides exactly that dossier on some key proteins in the iconic bacterium E. coli.

11 Nov 2010

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMX-30063, a synthetic defensin-mimetic antibiotic.

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon AG, Munich, and the University Hospital Rechts der Isar (Technical University Munich) announce their cooperation for the development of new, highly selective anti-infective agents against a novel protein target class of widely spread infectious diseases. Their joint project is supported in the framework of the top cluster support project of the German Federal Ministry of Education and Research, coordinated by BioM GmbH.

9 Nov 2010

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.

9 Nov 2010

GBS meningitis in infants still very serious

Although now less frequent because of preventive antibiotics, meningitis caused by group B streptococcal (GBS) bacteria is still a serious illness causing a high rate of death and severe complications in infants, reports a study in the November issue of The Pediatric Infectious Disease Journal.

9 Nov 2010

Antibiotic News and Research

Further Reading

Otoscopic exams critical for accurate diagnosis of ear infections in children

New inhalable dry powder antibiotic may reduce TB treatment time

FDA partners with CDC to kick off Get Smart about Antibiotics Week

UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

National campaign to highlight significance of antibiotic resistance

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Deinobiotics project receives €1.35 million for developing novel antibiotic, antifungal compounds

Report documents increase in R&D projects on developing world diseases

Research on E.Coli bacteria could help develop new vaccine for urinary tract infection

Targeted Genetics enters definitive agreements to acquire Biocontrol

NovaBay third quarter net loss increases to $1.6 million

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

MqsA and MqsR protein complex can disrupt drug-resistant biofilm formation

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

GBS meningitis in infants still very serious

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News